Where is Merck & Co., Inc. (MRK) Headed According to the Street?

Core Insights - Merck & Co., Inc. is recognized as a strong immunotherapy investment by hedge funds, with Deutsche Bank upgrading its rating to Buy and increasing the price target to $150 from $115, citing undervaluation due to Keytruda's patent concerns [1] Group 1: Company Developments - On February 11, Merck announced FDA approval for KEYTRUDA® and KEYTRUDA QLEX™ in combination with paclitaxel, for treating adults with PD-L1+ platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma [2] - KEYTRUDA QLEX's effectiveness is supported by well-controlled studies and additional data comparing its pharmacokinetic, efficacy, and safety profiles with KEYTRUDA [3] Group 2: Company Overview - Merck is a biopharmaceutical company focused on health solutions for disease treatment and prevention in both humans and animals, with its Pharmaceutical segment offering vaccines and therapeutic products [4]